PUBLICATIONS

  1. “Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers”, Meijie Tian, Katrina Jia, Jerry T. Wu, Adam T. Cheuk, Siteng Fang, Victor T. Ojo, Eleanor G. Pope, David Milewski, Yong Yean Kim, Hsien-Chao Chou, Avani Kelekar, Soumili Dey, Yunkai Yu, Mohammad Asikur Rahman, R. M. Naseer Khan, Oluwatobi Arisa, William D. Figg, Shyam K. Sharan, Zoe Weaver Ohler, Ludmila Szabova, Simone Difilippantonio, Borys Shor, L. Nathan Tumey, Jun S. Wei, Javed Khan, Cell Reports Medicine, 2026. https://doi.org/10.1016/j.xcrm.2026.102922
  2. “Subcutaneous Administration of Antibody-drug Conjugates”, Aiman A. Yaseen, Mohammad Asikur Rahman & L. Nathan Tumey*, Current Pharmacology Reports, 2026.  https://doi.org/10.1007/s40495-026-00442-5
  3. “Non-Glycosylated, Legumain-Cleavable ISACs Drive Potent Anti-Tumor Immunotherapy via a Bystander Effect”, Anqi Zhang, Mohan Reddy Mullapudi, Lina Wu, Michele Yi, Mohammad Asikur Rahman, Aiman A Yaseen, H Kayla Zhong, Tracy A Brooks, L Nathan Tumey*, Molecular Cancer Therapeutics, (2026) 25 (4): 622–634. https://doi.org/10.1158/1535-7163.MCT-25-1153
  4. “Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability”, Siteng Fang, Samantha R Benjamin, Lina Wu, Mohammad Asikur Rahman, Kayla K Elder, Victor T Ojo, Tao Zhang, Tracy A Brooks, L Nathan Tumey*, Journal of Medicinal Chemistry, 2025. https://doi.org/10.1021/acs.jmedchem.5c01908
  5. “Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity”, Victor T Ojo, Nicholas A Bianchi, Michele Z Yi, Samuel H Chung, Meghan E Gray, Mohammad Asikur Rahman, Kayla K Elder, Tao Zhang, Tracy A Brooks, L Nathan Tumey*, Journal of Medicinal Chemistry, 2025. https://doi.org/10.1021/acs.jmedchem.5c02681
  6. “Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability”, Mohan Reddy Mullapudi, Fanny Xu, Samantha R Benjamin, Katherine J Leong, Alexandra Maria Psaras, Mohammad Asikur Rahman, Tao Zhang, Tracy A Brooks, L Nathan Tumey*, Bioconjugate Chemistry, 2025.  https://doi.org/10.1021/acs.bioconjchem.5c00224
  7. “Development of potent FGFR4-targeted antibody-drug conjugate therapies for rhabdomyosarcoma and other cancers expressing FGFR4”, Meijie Tian, Katrina Jia, Jerry T Wu, Jun S Wei, Adam T Cheuk, Siteng Fang, Victor Ojo, Eleanor G Pope, Yong Yean Kim, Shyam K Sharan, Zoe Weaver Ohler, Ludmila Szabova, Simone Difilippantonio, Borys Shor, L Nathan Tumey, Javed Khan, Cancer Research, 2025, 85, 8_supplement_1, 3777 (American Association for Cancer Research) https://doi.org/10.1158/1538-7445.AM2025-3777
  8. “Advances and challenges in immunosuppressive antibody drug conjugates”, Aiman A Yaseen, L Nathan Tumey*, European Journal of Medicinal Chemistry, 2025, 291, 117576. https://doi.org/10.1016/j.ejmech.2025.117576
  9. “A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin cleavable ADC linkers”, Meghan E. Gray, Karina M. Zielinski, Fanny Xu, Kayla K. Elder, Steven J. McKay, Victor T. Ojo, Samantha R. Benjamin, Aiman A. Yaseen, Tracy A. Brooks, L. Nathan Tumey*, Xenobiotica, 2024, 54(8):458-468. DOI: 10.1080/00498254.2024.2352051
  10. “ValCitGlyPro-Dexamethasone Antibody Conjugates Selectively Suppress the Activation of Human Monocytes“, Justin M Howe, Siteng Fang, Kelsey A. Watts, Fanny Xu, Samantha R Benjamin and L. Nathan Tumey. RSC Medicinal Chemistry, 2023, 14, p2348. https://pubs.rsc.org/en/content/articlelanding/2023/md/d3md00336a
  11. “Synthesis and Optimization of 1-Substituted Imidazo[4,5-c]quinoline TLR7 Agonists“, Emma G. DeYoung, Justin M. Howe, Siteng Fang, Mullapudi Mohan Reddy, Jillian P. Handel, Jared T. Gillen Miller, Daniel R. Wheeler, and L. Nathan Tumey. ACS Med. Chem. Lett. 2023, 14, 10, 1358-68 https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.3c00260
  12.  “Evaluation of an ester-linked immunosuppressive payload: A case study in understanding the stability and cleavability of ester-containing ADC linkers”, Courtney P. Jackson, Siteng Fang, Samantha R. Benjamin, Tchilabalo Alayi, Yetrib Hathout, Sarah M. Gillen, Jillian P. Handel, Brittany M. Brems, Justin M. Howe, L. Nathan Tumey*; Bioorganic and Medicinal Chemistry Letters, 75, 2022. DOI: 10.1016/j.bmcl.2022.128953
  13. “Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates”, Siteng Fang, Brittany M Brems, Emmanuel O Olawode, Jared T Miller, Tracy A Brooks, L Nathan Tumey*; Molecular Pharmaceutics, 2022, 19, 9, 3228–3241. https://doi.org/10.1021/acs.molpharmaceut.2c00392
  14. “Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure”, AM Psaras, RK Carty, JT Miller, LN Tumey, TA Brooks; Genes 2022, 13 (8), 1440
  15. “ADC Linker Strategies for the Release of Alcohol-Containing Payloads”, Miller, Jared T., Tumey, L. Nathan*, Chemical Linkers in Antibody-Drug Conjugates (ADCs); Royal Society of Chemistry; 2021, pg 232-262.
  16. “The design and development of antibody-drug conjugates (ADCs) for the treatment of cancer”, Tumey, L. Nathan*, Burger’s Medicinal Chemistry, Drug Discovery and Development; Wiley Publishing, 2021. https://doi.org/10.1002/0471266949.bmc283
  17. “Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers”, Jared T Miller, Caitlin N Vitro, Siteng Fang, Samantha R Benjamin, L Nathan Tumey; Bioconjugate Chemistry, 2021, 32, 4, 842-858. DOI: https://doi.org/10.1021/acs.bioconjchem.1c00124
  18. “Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia”, Yoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, Wenyue Hu, Stephane Thibault, Fan Jiang, Mauricio Leal, Madan Katragadda, Andreas Maderna, Russell Dushin, Nadira Prashad, Manoj B Charati, Tracey Clark, L. Nathan Tumey, Xingzhi Tan, Andreas Giannakou, Edward Rosfjord, Hans-Peter Gerber, Lioudmila Tchistiakova, Frank Loganzo, Christopher J O’Donnell, Puja Sapra, Clinical Cancer Research, 2021, 27(2), 622-631. DOI: 10.1158/1078-0432.CCR-20-2149
  19. “PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers”; Edmund I Graziani, Matthew Sung, Dangshe Ma, Bitha Narayanan, Kimberly Marquette, Sujiet Puthenveetil, L Nathan Tumey, Jack Bikker, Jeffrey Casavant, Eric M Bennett, Manoj B Charati, Jonathon Golas, Christine Hosselet, Cynthia M Rohde, George Hu, Magali Guffroy, Hadi Falahatpisheh, Martin Finkelstein, Tracey Clark, Frank Barletta, Lioudmila Tchistiakova, Judy Lucas, Edward Rosfjord, Frank Loganzo, Christopher J O’Donnell, Hans-Peter Gerber, Puja Sapra; Molecular Cancer Therapeutics, 2020, 19, 10, 2068-2078. DOI: 10.1158/1535-7163.MCT-20-0237
  20. “Expanding the Versatility of Microbial Transglutaminase Using α-Effect Nucleophiles as Noncanonical Substrates.” Tak Ian Chio; Breanna R. Demestichas; Brittany M. Brems; Susan L. Bane*; L. Nathan Tumey*, Angew. Chemie, 59, 13814–13820, 2020. DOI: 10.1002/anie.202001830
  21. “An Overview of the Current ADC Discovery Landscape” (book chapter); L. N. Tumey; Antibody-Drug Conjugates (Methods in Molecular Biology), Humana, New York, NY, 2020. Page 1-22. DOI:10.1007/978-1-4939-9929-3_1
  22. “Detection and Removal of Small Molecule and Endotoxin Contaminants in ADC Preparations” (book chapter); J. Casavant, A. S. Ratnayake, S. Puthenveetil, L. N. Tumey; Antibody-Drug Conjugates (Methods in Molecular Biology), Humana, New York, NY, 2020. Page 291-299. DOI:10.1007/978-1-4939-9929-3_20
  23. “Case report: Albendazole associated psychosis”, Doughty, Bennett; Tumey, L. Nathan; Williams, Karen; Mental Health Clinician, November 2019, 9, 6, 397-400. DOI: 10.9740/mhc.2019.11.397
  24. “Antibody-Drug-Conjugates: Methods and Protocols”, Springer Publishing, 2019. (lead editor)
  25. “Thiolation of Q295: Site-specific conjugation of hydrophobic payloads without the need for genetic engineering”, Benjamin, Samantha R.; Jackson, Courtney P.; Fang,  Siteng; Carlson, Dane P.; Guo, Zhongyuan; Tumey, L. Nathan*, Molecular Pharmaceutics, 2019, 16,6, 2795-2807. DOI: 10.1021/acs.molpharmaceut.9b00323
  26. “Site-Specific Bioconjugation and Multi-Bioorthogonal Labeling via Rapid Formation of a Boron–Nitrogen Heterocycle”, Choi, Tak Ian; Gu, Han; Mukherjee, Kamalika; Tumey, L. Nathan Tumey*; Bane, Susan L. * (co-corresponding authors), Bioconjugate Chemistry, 2019, 30, 5, 1554-1564. DOI: 10.1021/acs.bioconjchem.9b00246
  27. “Natural Product Bis-​Intercalator Depsipeptides as a New Class of Payloads for Antibody-​Drug Conjugates”, Ratnayake, Anokha S.; Chang, Li-ping; Tumey, L. Nathan; Loganzo, Frank; Chemler, Joseph A.; Wagenaar, Melissa; Musto, Sylvia; Li, Fengping; Janso, Jeffrey E.; Ballard, T. Eric; Rago, Brian; Steele, Greg L.; Ding, WeiDong; Feng, Xidong; Hosselet, Christine; Buklan, Vlad; Lucas, Judy; Koehn, Frank E.; O’Donnell, Christopher J.; Graziani, Edmund I., Bioconjugate Chemistry, 2019, 30(1), 200-209.  DOI:10.1021/acs.bioconjchem.8b00843
  28. “Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity”, Zhou, Dahui; Casavant, Jeffrey; Graziani, Edmund I.; He, Haiyin; Janso, Jeffrey; Loganzo, Frank; Musto, Sylvia; Tumey, Nathan; O’Donnell, Christopher J.; Dushin, Russell, Bioorganic & Medicinal Chemistry Letters, 2019, 29(7), 943-957. DOI:10.1016/j.bmcl.2019.01.009
  29. “Next generation payloads for ADCs” (book chapter), L. Nathan Tumey*, Springer Publishing, “Innovations for Next-Generation Antibody-Drug Conjugates”, 2018.
  30. “ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers”, L. Nathan Tumey* and Sean Han, Current Topics in Medicinal Chemistry, 2017, 17(32), 3444-3462.
  31. “Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate”, Puthenveetil, Sujiet; He, Haiyin; Loganzo, Frank; Musto, Sylvia; Teske, Jesse; Green, Michael; Tan, Xingzhi; Hosselet, Christine; Lucas, Judy; Tumey, L. Nathan; Sapra, Puja; Subramanyam, Chakrapani; O’Donnell, Christopher J.; Graziani, Edmund I, 2017, PLoS One, 12(5), e0178452/1-e0178452/16. DOI:10.1371/journal.pone.0178452
  32. “Thinking Small and Dreaming Big: Medicinal Chemistry Strategies for Designing Optimal ADCs”, L. Nathan Tumey*, 2017, Medicinal Chemistry Reviews, Chapter 19, 2017, 52, 363-379.
  33. “Site selection: A case study in the identification of optimal cysteine engineered ADCs.”, L. Nathan Tumey*, Fengping Li, Brian Rago, Xiaogang Han, Frank Loganzo, Sylvia Musto, Edmund I. Graziani, Sujiet Puthenveetil, Jeffrey Casavant, Kimberly Marquette, Tracey Clark, Jack Bikker, Eric M. Bennett, Frank Barletta, Nicole Piche-Nicholas, Amy Tam, Christopher J. O’Donnell, Hans Peter Gerber, and Lioudmila Tchistiakova; AAPS Journal, 2017, 19(4), 1123-1135.
  34. “Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker.”, Brian Rago, L. Nathan Tumey, Cong Wei, Frank Barletta, Tracey Clark, Steve Hansel, and Xiaogang Han; Bioconjugate Chemistry, 2017, 28(2), 620-626.
  35. “Optimization of Tubulysin Antibody-Drug-Conjugates: A Case Study in Addressing ADC Metabolism”, L. Nathan Tumey, Carolyn A. Leverett, Beth Vetelino, Fengping Li, Brian Rago, Xiaogang Han, Frank Loganzo, Sylvia Musto, Guoyun Bai, Sai Chetan K. Sukuru, Edmund I. Graziani, Sujiet Puthenveetil, Jeffrey Casavant, Anokha Ratnayake, Kimberly Marquette, Sarah Hudson†, Venkata Ramana Doppala-pudi, Joseph Stock‡, Lioudmilla Tchistiakov, Andrew J. Bessire, Tracey Clark, Judy Lucas, Christine Hosselet, Christopher J. O’Donnell, and Chakrapani Subramanyam; ACS Medicinal Chemistry Letters, 2016, 7(11), 977-982. [Selected as cover article for November 2016 edition]
  36. “Calculated conjugated payload from immunoassay and LC–MS intact protein analysis measurements of antibody-drug conjugate”, Brian Rago, Tracey Clark, Lindsay King, Jenny Zhang, L. Nathan Tumey, Fengping Li, Frank Barletta, Cong Wei, Mauricio Leal, Steve Hansel*, & Xiaogang Han; Bioanalysis, 2016, 8(21), 2205-2217.
  37. “Natural Product Splicing Inhibitors: A New Class of Antibody-​Drug Conjugate (ADC) Payloads”, Puthenveetil, Sujiet; Loganzo, Frank; He, Haiyin; Dirico, Ken; Green, Michael; Teske, Jesse; Musto, Sylvia; Clark, Tracey; Rago, Brian; Koehn, Frank; Veneziale, Robert; Falahaptisheh, Hadi; Han, Xiaogang; Barletta, Frank; Lucas, Judy; Subramanyam, Chakrapani; O’Donnell, Christopher J.; Tumey, L. Nathan; Sapra, Puja; Gerber, Hans Peter; Ma, Dangshe; Graziani, Edmund I; Bioconjugate Chemistry, 2016, 27(8), 1880-1888.
  38. “Where Did the Linker-​Payload Go? A Quantitative Investigation on the Destination of the Released Linker-​Payload from an Antibody-​Drug Conjugate with a Maleimide Linker in Plasma”, Wei, Cong; Zhang, Guodong; Clark, Tracey; Barletta, Frank; Tumey, L. Nathan; Rago, Brian; Hansel, Steven; Han, Xiaogang; Analytical Chemistry, 2016, 88(9), 4979.
  39. “Development of Solid-​Phase Site-​Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates”, Puthenveetil, Sujiet; Musto, Sylvia; Loganzo, Frank; Tumey, L. Nathan; O’Donnell, Christopher J.; Graziani, Edmund; Bioconjugate Chemistry, 2016, 27(4) 1030.
  40. “In vivo biotransformations of antibody-​drug conjugates”, Tumey, L. Nathan; Rago, Brian; Han, Xiaogang; Bioanalysis, 2015, 7(13), 1649.
  41. “Mild method for succinimide hydrolysis on ADCs: Impact on ADC potency, stability, exposure, and efficacy”, L. Nathan Tumey, Manoj Charati, Tao He, Eric Sousa, Dangshe Ma, Xiaogang Han, Tracey Clark, Jeff Casavant, Frank Loganzo, Frank Barletta, Judy Lucas, and Edmund I. Graziani; Bioconjugate Chemistry, 2014, 25(10), p1871-1880.
  42. “Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4” Tumey, L. Nathan; Boschelli, Diane H.; Bhagirath, Niala; Shim, Jaechul; Murphy, Elizabeth A.; Goodwin, Deborah; Bennett, Eric M.; Wang, Mengmeng; Lin, Lih-Ling; Press, Barry; Shen, Marina; Frisbie, Richard K.; Morgan, Paul; Mohan, Shashi; Shin, Julia; Rao, Vikram R., Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2066-2072.
  43.  “Recent advances in antibody-​drug conjugates” Graziani, Edmund I.; Tumey, L. Nathan, RSC Drug Discovery Series, 2013, 36 (Biotherapeutics), 145-175.
  44. “CRTH2 antagonists” Tumey, L. Nathan, RSC Drug Discovery Series, 2012, 26 (Anti-Inflammatory Drug Discovery), 104-134.
  45. “5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCθ: Optimization of enzymatic and functional activity.”, Tumey, L. Nathan; Bhagirath, Niala; Brennan, Agnes; Brooijmans, Natasja; Lee, Julie; Yang, Xiaoke; Boschelli, Diane H., Bioorg. Med. Chem, 2009, 17, 7933-7948.
  46. “First generation 5-vinyl-3-pyridinecarbonitrile PKC-theta inhibitors”, Niu, Chuansheng; Boschelli, Diane H.; Tumey, L. Nathan; Bhagirath, Niala; Subrath, Joan; Shim, Jaechul; Wang, Yan; Wu, Biqi; Eid, Clark; Lee, Julie; Yang, Xiaoke; Brennan, Agnes; Chaudhary, Divya, Bioorg. Med. Chem. Lett., 2009, 19(20), 5829-5832.
  47. “2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKC-theta”, Tumey, L. Nathan; Boschelli, Diane H.; Lee, Julie; Chaudhary, Divya.  Bioorg. Med. Chem. Lett.,2008, 18(15), 4420-4423.
  48. “A facile, scalable preparation of 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carbonitriles”, Tumey, L. Nathan; Bhagirath, Niala; Wu, Biqi; Boschelli, Diane H., Tetrahedron Lett., 2008, 49(48), 6850-6852.
  49. “Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.”, Robarge, Michael J.; Bom, David C.; Tumey, L. Nathan; Varga, Norbert; Gleason, Elizabeth; Silver, Daniel; Song, Jianping; Murphy, Steven M.; Eckema, George; Doucette, Chris; Hanniford, Doug; Palmer, Marc; Pawlowski, Gary; Danzig, Joel; Loftus, Margaret; Hunady, Karen; Sherf, Bruce A; Mays, Robert W; Stricker-Krongrad, Alain; Brunden, Kurt R; Harrington, John J; Bennani, Youssef L, Bioorg. Med. Chem. Lett. 2005, 15(6), 1749-1753.
  50. “The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors”, Tumey, L. N.; Bom, D.; Huck, B.; Gleason, E.; Wang, J.; Silver, D.; Brunden, K.; Boozer, S.; Rundlett, S.; Sherf, B.; Murphy, S.; Dent, T.; Leventhal, C.; Bailey, A; Harrington, J; Bennani, Y. L.”, Bioorg. Med. Chem. Lett. 2005, 15(2), 277-81.
  51. “The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors”, Tumey, L.N.; Huck, B.; Gleason, E.; Wang, J.; Silver, D.; Brunden, K.; Boozer, S.; Rundlett, S.; Sherf, B.; Murphy, S.; Bailey, A.; Dent, T.; Leventhal, C.; Harrington, J.; Bennani, Y.L., Bioorg. Med. Chem. Lett., 2004, 14(19), 4915-8.
  52. “High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-Activity Relationships in Novel Inhibitors of Escherichia coli LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties”, Pirrung, M. C.; Tumey, L. N.; McClerren, A. L.; Raetz, C. R. H., J. Am. Chem. Soc., 2003, 125 (6), 1575-1586.
  53. “Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups”, Pirrung, M.C.; Tumey, L.N.; Raetz, C.R.; Jackman, J.E.; Snehalatha, K.; McClerren, A.L,; Fierke, C.A.; Gantt, S.L.; Rusche, K.M., J. Med. Chem., 2002, 45(19), 4359-70.
  54. “19F-Encoded Combinatorial Libraries:  Discovery of Selective Metal Binding and Catalytic Peptoids”, Michael C Pirrung; Kaapjoo Park; L Nathan Tumey, J. Comb. Chem., 2002, 4, 4, 329-344.
  55. “Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.”, Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR., J. Biol. Chem., 2000, 275(15), 11002-9.
  56. “Oxazoline Synthesis from Hydroxyamides by Resin Capture and Ring-Forming Release”, Michael C. Pirrung; L. Nathan Tumey, J. Comb. Chem., 2000, 2, 6, 675-680.